InspireMD Q1 revenue jumps 122%, beats estimates on product demand

InspireMD

04/05/2026 21:15

Overview

Medical device maker's Q1 revenue rose 122% yr/yr, beating analyst expectations

Net loss for Q1 was narrower than analyst estimates

Company initiated voluntary U.S. recall of CGuard Prime 135 cm for technical enhancements

Outlook

InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026

Company expects FDA approval of CGuard Prime 80 cm for TCAR procedures in H2 2026

Company says TCAR program remains unaffected by voluntary recall of CGuard Prime 135 cm

Result Drivers

PRODUCT DEMAND - Co said Q1 revenue growth was driven by increased demand for CGuard Prime in the U.S. and original CGuard in international markets

SALES MIX SHIFT - Gross margin improved due to a higher proportion of U.S. sales, which carry higher margins, partly offset by an inventory impairment charge

HIGHER OPERATING EXPENSES - Increased operating expenses were mainly due to greater headcount-related costs and investments to support U.S. commercialization

Company press release: ID:nGNX5Zd22l

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$3.40 mln
$2.70 mln (3 Analysts)
Q1 Net Income
Beat
-$13.69 mln
-$15.48 mln (3 Analysts)
Q1 Income From Operations
Beat
-$13.98 mln
-$15.64 mln (3 Analysts)
Q1 Basic EPS
-$0.16
Q1 Gross Profit
$687,000
Q1 Operating Expenses
$14.67 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for InspireMD Inc is $4.00, about 247.8% above its May 1 closing price of $1.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)